Week in Review: FDA confirms recall for vascular device | BATMAN to the rescue | Prasugrel after PCI | GLP-1 drugs & AFib

The issue at the heart of this recall has been linked to three patient deaths. 

A total of 24 adverse safety incidents—including cases of diabetic ketoacidosis—have been linked to this issue.

TAVR procedures with a higher implant depth are associated with certain clinical benefits after one year, according to a new study of data from more than 600 patients.

LVOT obstruction is a serious complication of TMVR. BATMAN may help protect patients from LVOT obstruction without leading to any additional risks.

This is a Class I recall, according to the FDA. Care teams may need to send in their equipment so that specific hardware updates can be performed.

The new AI-enabled resource works like a search engine and delivers answers in seconds.

Researchers explored data from nearly 800 patients, focusing on a wide variety of outcomes.

"Prasugrel provided the optimal balance between efficacy and safety," researchers noted in a new meta-analysis. 

Physicians from all specialties, not just cardiology, have been hoping for legislation like this for years.

Kenneth Bilchick, MD, spoke to Cardiovascular Business about new data he presented at Heart Rhythm 2026.